Common Side Effects of GLP-1 Medications: What You Need to Know

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

GLP-1 receptor agonists like liraglutide and semaglutide effectively manage type 2 diabetes and obesity but commonly cause GI side effects such as nausea and vomiting. Rare risks include pancreatitis, thyroid tumors, and gallbladder disease, warranting careful monitoring.

# Side Effects of GLP-1 Medications: What You Need to Know

Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized the treatment of type 2 diabetes and obesity, offering effective glucose control and weight loss benefits. These medications, including popular drugs like liraglutide (Victoza, Saxenda), semaglutide (Ozempic, Wegovy), and dulaglutide (Trulicity), mimic the action of the naturally occurring GLP-1 hormone. While they provide significant therapeutic advantages, it is important to understand their potential side effects, dosing guidelines, and safety considerations.

This article provides a comprehensive overview of the common and rare side effects associated with GLP-1 receptor agonists, supported by clinical evidence, and offers practical advice for users and healthcare providers.

---

What Are GLP-1 Medications?

GLP-1 receptor agonists are injectable or oral medications that stimulate GLP-1 receptors in the pancreas and brain. They enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety. These effects contribute to better blood sugar regulation and reduced appetite, making GLP-1 drugs a preferred option for managing type 2 diabetes and obesity.

Common GLP-1 receptor agonists include:

  • Liraglutide (Victoza, Saxenda)
  • Semaglutide (Ozempic, Wegovy)
  • Dulaglutide (Trulicity)
  • Exenatide (Byetta, Bydureon)
  • Albiglutide (Tanzeum) [less commonly used]

    • ---

    Common Side Effects of GLP-1 Medications

    Gastrointestinal Symptoms

    The most frequently reported side effects of GLP-1 receptor agonists are gastrointestinal (GI) related. These include:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal pain
  • Indigestion

    • These symptoms often occur during the initial weeks of treatment as the body adjusts to the medication and tend to diminish over time. Slow dose escalation protocols can help minimize GI side effects.

    Evidence: In clinical trials, up to 40% of patients report nausea, with a smaller proportion experiencing vomiting or diarrhea. For example, the STEP 1 trial of semaglutide for obesity reported nausea in approximately 20% of participants.

    Hypoglycemia (Low Blood Sugar)

    GLP-1 receptor agonists alone have a low risk of causing hypoglycemia because they stimulate insulin secretion in a glucose-dependent manner. However, when combined with other diabetes medications such as sulfonylureas or insulin, the risk of hypoglycemia increases.

    Clinical note: Patients on combination therapy should be monitored closely, and medication doses may need adjustment to reduce hypoglycemia risk.

    ---

    Less Common but Serious Side Effects

    Pancreatitis

    Cases of acute pancreatitis have been reported in patients using GLP-1 receptor agonists, though a direct causal relationship remains uncertain. Patients should be advised to seek medical attention if they experience severe abdominal pain, nausea, or vomiting.

    Protocol: Discontinue GLP-1 therapy if pancreatitis is suspected until evaluation is complete.

    Thyroid C-Cell Tumors

    Animal studies have shown an increased risk of thyroid C-cell tumors with some GLP-1 receptor agonists, particularly liraglutide and semaglutide. However, this risk has not been confirmed in humans.

    Guidance: GLP-1 drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).

    Gallbladder Disease

    Increased risk of gallbladder-related events, such as cholelithiasis (gallstones), has been reported, likely related to rapid weight loss associated with these drugs.

    ---

    Dosing and Administration Considerations

    GLP-1 receptor agonists are typically administered via subcutaneous injection once daily or once weekly, depending on the formulation.

    Examples of dosing protocols:

  • Liraglutide (Victoza/Saxenda): Start at 0.6 mg daily for one week; increase weekly by 0.6 mg increments up to 1.8 mg daily for diabetes (Victoza) or up to 3.0 mg daily for weight management (Saxenda).
  • Semaglutide (Ozempic/Wegovy): Start at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg weekly; may escalate to 1.0 mg or 2.4 mg weekly depending on indication.
  • Dulaglutide (Trulicity): Typically started at 0.75 mg weekly